Drug Interactions between Azithromycin Dose Pack and bupivacaine / hydromorphone
This report displays the potential drug interactions for the following 2 drugs:
- Azithromycin Dose Pack (azithromycin)
- bupivacaine/hydromorphone
Interactions between your drugs
No interactions were found between Azithromycin Dose Pack and bupivacaine / hydromorphone. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Azithromycin Dose Pack
A total of 376 drugs are known to interact with Azithromycin Dose Pack.
- Azithromycin dose pack is in the drug class macrolides.
-
Azithromycin dose pack is used to treat the following conditions:
- Babesiosis
- Bacterial Endocarditis Prevention
- Bacterial Infection
- Bartonellosis
- Bronchitis
- Cervicitis
- Chancroid
- Chlamydia Infection
- COPD, Acute
- Cystic Fibrosis
- Gonococcal Infection, Uncomplicated
- Granuloma Inguinale
- Legionella Pneumonia
- Lyme Disease, Erythema Chronicum Migrans
- Middle Ear Infections
- Mycobacterium avium-intracellulare, Prophylaxis
- Mycobacterium avium-intracellulare, Treatment
- Mycoplasma Pneumonia
- Nongonococcal Urethritis
- Pelvic Inflammatory Disease
- Pertussis
- Pertussis Prophylaxis
- Pharyngitis
- Pneumonia
- Sinusitis
- Skin and Structure Infection
- Skin or Soft Tissue Infection
- STD Prophylaxis
- Tonsillitis/Pharyngitis
- Toxoplasmosis
- Typhoid Fever
- Upper Respiratory Tract Infection
bupivacaine / hydromorphone
A total of 527 drugs are known to interact with bupivacaine / hydromorphone.
- Bupivacaine / hydromorphone is in the drug class narcotic analgesic combinations.
- Bupivacaine / hydromorphone is used to treat Pain.
Drug and food interactions
HYDROmorphone food
Applies to: bupivacaine / hydromorphone
GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including hydromorphone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.
GENERALLY AVOID: Consumption of alcohol while taking sustained-release formulations of hydromorphone may cause rapid release of the drug, resulting in high systemic levels of hydromorphone that may be potentially lethal even in opioid-tolerant patients. Alcohol appears to disrupt the extended release mechanism, causing 'dose-dumping' into the bloodstream. In 48 healthy volunteers, coadministration of a 12 mg dose of sustained-release hydromorphone with 240 mL of 40% (80 proof) alcohol resulted in a mean peak hydromorphone concentration (Cmax) approximately six times greater than when taken with water. One subject had a 16-fold increase in hydromorphone Cmax with 40% alcohol compared to water. In some subjects, coadministration with 8 ounces of 4% alcohol (equivalent to 2/3 of a typical serving of beer) resulted in almost twice the hydromorphone Cmax than when coadministered with water. The effect of alcohol was more pronounced in a fasted state.
MANAGEMENT: Patients taking sustained-release formulations of hydromorphone should not consume alcohol or use medications that contain alcohol on days of hydromorphone dosing. In general, potent narcotics such as hydromorphone should not be combined with alcohol.
References (3)
- Levine B, Saady J, Fierro M, Valentour J (1984) "A hydromorphone and ethanol fatality." J Forensic Sci, 29, p. 655-9
- (2001) "Product Information. Dilaudid (hydromorphone)." Knoll Pharmaceutical Company
- FDA. U.S. Food and Drug Administration (2005) Healthcare Professional Sheet. FDA Alert [07/2005]: alcohol-palladone interaction. http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Palladone
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.